T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Julia Palecki,Amman Bhasin,Andrew Bernstein,Patrick J. Mille,William J. Tester,Wm. Kevin Kelly,Kevin K. Zarrabi

DOI: https://doi.org/10.1080/15384047.2024.2356820

2024-05-29

Cancer Biology & Therapy

Abstract:Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as well as immune effector cells, thus promoting an immune response against cancer cells. Prostate cancer is rich in tumor associated antigens such as, but not limited to, PSMA, PSCA, hK2, and STEAP1 and there is strong biologic rationale for employment of T-cell redirecting BiTEs within the prostate cancer disease space. Early generation BiTE constructs employed in clinical study have demonstrated meaningful antitumor activity, but challenges related to drug delivery, immunogenicity, and treatment-associated adverse effects limited their success. The ongoing development of novel BiTE constructs continues to address these barriers and to yield promising results in terms of efficacy and safety. This review will highlight some of most recent developments of BiTE therapies for patients with advanced prostate cancer and the evolving data surrounding BiTE constructs undergoing clinical evaluation.

oncology

What problem does this paper attempt to address?

The paper primarily discusses the application and progress of bispecific T-cell engagers (BiTEs) as a novel immunotherapy in the treatment of advanced prostate cancer.

The core objective of the paper is to review and evaluate the potential and challenges of bispecific T-cell engagers as a new form of immunotherapy in treating advanced prostate cancer. Specifically, it covers the following aspects:

1. **Background Introduction**: First, it introduces the current status of prostate cancer as the second leading cause of cancer death among men in the United States, and the limitations of current treatment methods such as surgery, radiotherapy, and androgen deprivation therapy, despite their effectiveness.

2. **T-cell Redirected Immunotherapy**: It then introduces the concept of T-cell redirected immunotherapy, focusing on bispecific T-cell engagers (BiTEs), which are engineered antibodies capable of linking tumor-associated antigens (TAA) and immune effector cells (such as T cells), thereby promoting an immune response against cancer cells.

3. **Prostate Cancer-Related Antigens**: It lists in detail some tumor-associated antigens expressed in prostate cancer, such as PSMA, PSCA, hK2, and STEAP1, and emphasizes the importance of these antigens as targets for BiTEs.

4. **Early BiTEs Research Results**: It reviews the performance of several early BiTEs (such as AMG 212, AMG160, APVO414, etc.) in clinical trials, including their safety, efficacy, and some challenges encountered.

5. **Development of Contemporary BiTEs**: It then introduces several new BiTEs currently undergoing clinical research, such as AMG509 and REGN5678, highlighting the progress these new BiTEs have made in overcoming the limitations of early BiTEs.

In summary, this paper aims to explore the opportunities and challenges faced by bispecific T-cell engagers as a new therapy for treating advanced prostate cancer by reviewing and analyzing existing research results.